Sabrina Liu Amy Ma Thongchai Rattanaruengyot Anand Sharma. Presents ViroPharma Incorporated. Another Biotech? Why Harold & Kumar hate this
|
|
- Caren Mason
- 5 years ago
- Views:
Transcription
1 Sabrina Liu Amy Ma Thongchai Rattanaruengyot Anand Sharma Presents ViroPharma Incorporated Another Biotech? Why Harold & Kumar hate this Biotechs are hard to understand. We can t project cash flows. They re traded at crazy multiples! We re value investors!!! We hate Big Companies! No!!!! Asian and Indian combination. Whitecastle rocks! 1
2 Why ViroPharma is Different Why we love it They have 5 drugs in the pipeline. Small Cap. We can value this! Stock is likely to be mis-priced. Biotechs are expensive? This is trading at 5 times EV/ Revenue 8 times EV/EBITDA More on the Difference I m lovin it Only companies like Piper Jaffrey cover this company. We can see hidden value in this investment! Ok we ll get serious now. Let s start the industry overview 2
3 The Biotech First started in 1971 but really took off in the last 10 years Big players are Amgen, Genentech, Genzyme Sharpshooters vs. Carpet Bombers Competitors Anemia, Arthritis, Carcinoma Arthritis, Multiple Sclerosis Pompe Disease, Multiple Sclerosis HIV/AIDS, Hepatitis B Respiratory, Chemotherapy, Influenza Leukemia, Cancer 3
4 Drivers Population over 65 to increase by 73% Over 40% of industry revenues Old people are also living longer States spending $1bn towards biotech Hardest part of industry is seed capital to start pipeline Numbers Over $60bn with 18.9% growth in 2005 Avg. R&D expenses have decreased from ~60% % 2005 (of rev.) Firms trade at very high multiples Huge margins in this industry 55% to 90% is typical Biotech P/E 45.06x PEG 1.92x EV/EBITDA 15.31x 4
5 From Phase I to FDA Approval Phase I (~.5-1yr) Assess safety of drug in small # of patients 47% of drugs make it to market Phase II (~1-2 yrs) Determine basic dosing, safety and effectiveness in patients with the problem 73% of drugs make it to market Phase III (~2-4 yrs) Same as Phase II but bigger, with placebo etc. 95% of drugs make it to market Fast Track (i) Success rates from SCRIP magazine study of biotech industry & success rate study by DiMasi From Phase I to FDA Approval Reasons for Failure 15% 40% 15% 30% Efficacy Economics Safety Other 5
6 ViroPharma Overview $900 mm biotech company 5 main drugs in the pipeline 49 employees Core expertise in infectious diseases No debt, positive cash flow History Incorporated in 1994 Acquired rights to Maribavir in 2003 First product, Vancocin, launched in 2004 Paid Eli Lilly $116 mm Maribavir went to Phase III in 2006 HCV-796 in Phase II 6
7 Product Overview Products Disease Phase Vancocin Staphylococcal M Maribavir Herpes III HCV Hepatitis II NTX Clostridium Difficile PC Pleconaril Common Cold D Product Summary Discontinued 9 Market 2 Phase III Phase II Pre Clinical Number of Products Business Structure Develops and sells drugs Outsources production to third parties Sells drugs to wholesalers Low capital expenditures No inventory Receives grants and milestone payment 7
8 Revenue Sources 1. Product Sales 2. License Fees and Milestone Fees 3. Grant and Other Revenue LTM Net Product Sales $0 $8,348 $125,853 $168,480 License Fee and Milestone Fee 1,084 13,070 6, Grant and Other Revenue Total $1,612 $22,389 $132,417 $169,044 Note: $ in thousands Revenues and Profitability First revenue stream in 2004 CapEx peaked in 2004 due to purchase of rights from Eli Lilly $200,000 $150,000 $100,000 $50,000 $0 CapEx and R&D Capital Expenditures R&D -$50, LTM Note: $ in thousands $200,000 $150,000 $100,000 $50,000 $0 -$50,000 Revenues and EBITDA Revenues EBITDA LTM 8
9 Growth Opportunities Marivabir HCV Pleconaril We just need any of these drugs to be marketed and give ViroPharma more than $120mm of Free Cash Flow and then my sunflower will be happy $120mm ( ) = $1,000mm Partnerships Teams up with larger companies R&D Profit Sharing Agreement ViroPharma receives capital Sometimes makes product acquisition 9
10 Tax Benefits $60 mm of NOLs in balance by 2005 We expect benefits to end by LTM Tax Benefits $37,805 $14,975 Numbers in thousands NOLs = Net Operation Losses Carryforwards Management Team Coming from senior leadership positions from other companies (Amgen, etc.), their skill and their passion for results will provide the catalyst for ViroPharma's future. It s all about the management baby! Michel de Rosen CEO Colin Broom, M.D. Vice President, Chief Scientific Officer Thomas F. Doyle Vice President, General Counsel Vincent J. Milano CFO and COO 10
11 Management s Outlook Drugs launching in the next few years Growth of portfolio Outlook is so sweet baby! I know! Only FDA approved antibiotic to treat two intestinal infections sold in U.S. Clostridium difficile infections Staphylococcal infections Patients increasing by 20% / year Bought back rights from Eli Lilly Currently no competing drug in market 11
12 95% of 2005 revenues 3Q06 sales increased 54.5% compared to 3Q05 and overall sales in 2006 increased 49.8% compared to 2005 Vancocin Revenue Qtr1 Qtr2 Qtr3 Qtr4 Annual 2006 $29.23 $43.82 $55.10 NA NA NA NA NA Note: $ in millions High seasonal demands in spring Filed Petition for Stay of Action in March with FDA Strong case against OGD s proposal to modify bioequivalence standards for generics 2012 earliest estimate of generics entering the market if generic companies start at it today 12
13 Maribavir CMV Overview A type of herpes Infection rate between 50%-80% of adults by 40 years of age For immunocompromised individuals, CMV can lead to serious diseases or deaths Stem cell/ bone marrow or solid organ transplantation 19,000 stem cell/ bone marrow transplants in America 26,000 solid organ transplants Maribavir Product Overview New type of CMV drug Designed for drug-resistant CMV strains No neutropenia and renal toxicity Unlike currently available anti-cmv agents that inhibit CMV DNA polymerase, maribavir inhibits viral DNA assembly and inhibits egress of viral capsids from the nucleus of infected cells. Maribavir is active in vitro against strains of CMV that are resistant to commonly used anti- CMV drugs. 13
14 Herpes Maribavir s Competitors Many types of herpes Eye, genital, etc Not many competitors for Maribavir Received Fast Track approval in Feb06 14
15 HCV-796 Treats Hepatitis C (currently no vaccines or treatments for this) $2.5bn currently towards sales of diseases that address Close to 5million cases in the US and 200m worldwide Polymerase inhibitor VERY successful early Phase, possible fast track Works well as a combo package In conference calls, as well as industry analyst estimates, could be a $400 $500mm per annum at peak Already well underway with Phase II (expected to get results in Q107) Possible Fast Track drug HCV-796 Likelihood of success: 15
16 HCV-796 Intranasal Pleconaril Antiviral product used for the treatment of the common cold ViroPharma sold to Schering-Plough: Cost them $1.9 mm to make Sold for initial licensing fee of $10 mm + $6 mm for remaining inventory $65 million in milestone payments (get it in 07) Royalties on Schering-Plough's sales of intranasal pleconaril in licensed territories 16
17 NTX Not even wasting our time because it s in Phase I Generic competition for Vancocin Failure for Maribavir and HCV-796 Failure to come up with new pipeline Changes in prescription pattern Regulation 17
18 Investment Catalysts: Presentation at American Society of Hematology in Dec Phase II data for HVC in Q107 Better than expected sales data Disease growth! s we can understand Products that there s a market for Buy! Relative analysis yields attractive upsides For Biotech, we look at P/E, PEG Mean Median EV/Revenue EV/EBITDA P/E PEG Year 6.61x 5.72x 15.3x 14.1x 45.06x 25.45x 1.92x 6.22x 5.64x 15.9x 14.6x 24.30x 22.20x 1.30x ViroPharma Selected Multiple Implied Price Upside EV/Revenue EV/EBITDA P/E PEG Year 6.61x 5.72x 15.3x 14.1x 23.00x 20.00x 1.20x $1,117.8 $1,200.8 $1,658.0 $2,848.6 $37.35 $55.09 $ % 23% 69% 191% 142% 257% 296% 18
19 Revenue Projection Probability of success Maribavir 90%, HCV 80% Revenues Vancocin $210,000 $315,000 $330,000 $330,000 $330,000 Maribavir 50,000 75, , ,000 HCV , , ,000 Total $210,000 $365,000 $705,000 $860,000 $880,000 Revenues Vancocin $0 $0 $0 $0 $0 Maribavir 200, , , , ,000 HCV , , , , ,000 Total $550,000 $550,000 $550,000 $550,000 $550,000 Note: $ in thousands Conservative Assumptions WACC is 15% (cost of equity) Bloomberg beta 0.9 Vancocin revenue $0 after 2011 No value to milestones or grants Didn t show any margin changes Management said will get better International sales projections not included 19
20 Q&A 20
Sobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth. Investor Presentation l 13 November 2018
Sobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth Investor Presentation l 13 November 2018 Forward looking statements In order to utilise the Safe Harbor provisions
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationGlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review
GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationAMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA
News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone (805) 447-1000 Fax (805) 499-3507 www.amgen.com AMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION
More informationChimerix Announces First Quarter 2017 Financial Results
May 9, 2017 Chimerix Announces First Quarter 2017 Financial Results - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical
More informationInvestment Proposal. March 19th, Jenny Park Arthi Sairam. LinkedIn Corporation (NYSE- LNKD)
Investment Proposal LinkedIn Corporation (NYSE- LNKD) March 19th, 2016 Jenny Park Arthi Sairam Agenda I. Executive Summary II. Business Overview A. Company Overview B. Free Solutions C. Monetized Solutions
More informationREGENXBIO Inc. Ticker: RGNX
REGENXBIO Inc. Ticker: RGNX I know what you are thinking. You are about to read another biotech report with more acronyms than words you know the definitions. I promise you this report is written in layman
More informationDear shareholders, Víctor Grífols President and CEO of Grifols
ANNUAL 2012 REPORT Dear shareholders, Grifols ushered in a new era in 2012, one that has seen the company become the world s third-largest producer of plasma-derived medicines following the acquisition
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationSciGen Limited. Annual General Meeting Managing Director s Presentation. 28 February 2005
SciGen Limited Annual General Meeting Managing Director s Presentation 28 February 2005 Mr Mark Compton Chief Executive Officer and Managing Director SciGen Limited Biopharmaceutical company Expert focus
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationSecond Quarter 2017 Earnings Teleconference. August 1, 2017
Second Quarter 2017 Earnings Teleconference August 1, 2017 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information 3 Our discussions
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationQ Earnings Presentation. July 18 th, 2014
Q2 2014 Earnings Presentation July 18 th, 2014 The SAFE HARBOR Statement under the Private Securities Litigation Reform Act of 1995 Statements included in this announcement that are not historical facts
More informationPharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer
Pharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer R.W. Baird Growth Stock Conference 2008 14 May 2008 Safe Harbor Except for historical information, all of the statements,
More informationPharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer
Pharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer Banc of America Healthcare Conference 2008 13 May 2008 Safe Harbor Except for historical information, all of the statements,
More informationInvestor Relations Presentation. September 2014
Investor Relations Presentation September 2014 Forward Looking Statements This presentation contains historical information and forward-looking statements within the meaning of The Private Securities Litigation
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationAltimmune Inc. (NASDAQ:ALT)
NEW YORK SÃO PAULO SHANGHAI Altimmune Inc. (NASDAQ:ALT) - Specialty Pharma Research Note Data for 2 clinical stage candidates -- a potential cure for chronic hepatitis B and a novel treatment for seasonal
More informationAmgen, Inc. Rating: Buy
BIOTECHNOLOGY Shiv Kapoor (917) 238-8207 skapoor@morganjoseph.com Company Update / Price Target Change / Estimates Change August 25, 2008 Key Metrics AMGN - NASDAQ $64.01 Pricing Date 08/22/2008 Price
More informationCompany Name: Huron Consulting Group, Inc. (HURN) Event: William Blair 2018 Growth Stock Conference Date: June 14, 2018
Company Name: Huron Consulting Group, Inc. (HURN) Event: William Blair 2018 Growth Stock Conference Date: June 14, 2018 Okay. We're going to go ahead
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationCogstate Ltd. (CGS) Summary (AUD) Key Financials (A$ million) Share Price Graph (AUD)
Cogstate Ltd. (CGS) 7 August, 2017 Outperform 4Q17: Slow Growth, but CGS is Well-Positioned Price Target: $1.27 Elyse Shapiro eshapiro@taylorcollison.com.au +61 4 9126 7142 Summary (AUD) Market Capitalisation
More informationNastech Pharmaceutical Company Inc. Company Presentation
Nastech Pharmaceutical Company Inc. Company Presentation 2005 Nastech Forward-Looking Statements Statements made in this presentation may be forward-looking statements within the meaning of Federal Securities
More informationPharmaceutical Business Development
Pharmaceutical Business Development Investor Day - June 13, 2012 NASDAQ:CBLI Safe Harbor This presentation includes forward-looking statements and predictions, including statements about potential revenue-bearing
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 21, 2018 David Bautz, PhD (312) 265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Motif Bio Plc (MTFB-NASDAQ)
More informationNet Debt/EBITDA PEG EV/ Large-Cap Biotech (MM) (MM) LTM 2015E 2016E 2015E 2016E Book LTM NTM Unlevered FCF. Market Cap EV EV/EBITDA P/E Price/
To: From: Kelvin Li Danny Kim Date: August 18 th, 2015 Re: COMPANY DESCRIPTION Celgene Corporation (NYSE:CELG) COMPANY PROFILE INVESTMENT PROFILE Industry: Biotechnology Current (Proposed) Investment Size:
More informationFresenius Investor News
Analysts Meeting and Live video webcast today Fresenius Medical Care at 2.30 p.m. CET / 8.30 a.m. EDT Fresenius AG at 4.30 p.m. CET / 10.30 a.m. EDT health care worldwide May 4, 2005 Contact: Birgit Grund
More informationOn Helix. 02 July Harren Jhoti President & CEO
On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationCL King Best Ideas Conference
Leadership in Surface Modification and Drug Delivery Phil Ankeny, Senior Vice President and CFO CL King Best Ideas Conference The Omni Berkshire Place Hotel September 19, 2007 Safe Harbor Statement Some
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More information100M sufferers in US (2.2B worldwide) 65% of people ages NOCTURIA is the #1 urology complaint of men and women 55-84
INVESTOR DECK PAXEROL for NOCTURIA 100M people in the US suffer from a problem for which we have a strong solution. The patents are issued. We are raising funds for EU launch and FDA trial. David A. Dill,
More informationOraSure Technologies Jefferies 2016 Healthcare Conference
OraSure Technologies Jefferies 2016 Healthcare Conference Forward-Looking Statements These slides and the associated presentation contain certain forwardlooking statements, including statements with respect
More informationA Biotech Blockbuster in the $60 Billion Pet Industry. A Biotech Blockbuster in the $60 Billion Pet Industry
A Biotech Blockbuster in the $60 Billion Pet Industry Artana Therapeutics: Off the Radar and Undervalued Our next profile is a unique biopharma that is literally for the dogs, and that is a good thing
More informationFourth quarter and full year results to December 31, 2013
Fourth quarter and full year results to December 31, 2013 Shire plc February 13, 2014 Flemming Ornskov, MD Chief Executive Officer Graham Hetherington Chief Financial Officer Our purpose We enable people
More informationFresenius Investor News
health care worldwide October 31, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More information(NYSE: ROK) Rating: BUY Price Target: $ Industry: Electrical Components and Equipment. Investment Action & Thesis. Key Investment Highlights
Rating: BUY Price Target: $81.50 Industry: Electrical Components and Equipment Close 9/28/2012 Price $69.55 52 Wk $53.06 - $84.71 Shares Out (mm) 141.1 Mkt. Cap(mm) $9,816.9 Source: Capital IQ Basic Information
More informationA solid commercial dynamic: 4 new license agreements since the beginning of 2008
Press release Results for the 1 st half-year in line with VIVALIS targets and strategy A solid commercial dynamic: 4 new license agreements since the beginning of 2008 Enhanced financial strength and visibility
More informationLUPIN LIMITED. J.P. Morgan Healthcare Conference January 8 th, Vinita Gupta, CEO
LUPIN LIMITED J.P. Morgan Healthcare Conference January 8 th, 2019 Vinita Gupta, CEO Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements.
More informationData Protection for Biologics: Balancing Innovation Incentives and Cost Savings Henry Grabowski
Data Protection for Biologics: Balancing Innovation Incentives and Cost Savings Henry Grabowski Health Industry Forum Washington, DC June 11, 2009 What is Data Protection? Data protection is the period
More informationNext Generation Eye Care
Next Generation Eye Care Company Overview Ocular Science is an innovative biotech and pharmaceutical company that offers paradigm-shifting eye care products to physicians and their patients in a cost-effective
More informationASX Announcement MAYNE PHARMA REPORTS STRONGER 1HFY19 RESULTS
22 February 2019 MAYNE PHARMA REPORTS STRONGER 1HFY19 RESULTS Revenues of $274.4m, an increase of 13% on 1HFY18 Reported EBITDA of $65.4m, an increase of 184% on 1HFY18 Underlying EBITDA of $81.2m, an
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationSpectrum Pharmaceuticals Jefferies 2015 Global Healthcare Conference
Spectrum Pharmaceuticals Jefferies 2015 Global Healthcare Conference June 3 rd, 2015 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements
More informationICL. Divestment of the Fire Safety and Oil Additives Businesses. December 7, :30 GMT
ICL Divestment of the Fire Safety and Oil Additives Businesses December 7, 2017 13:30 GMT This is Conference # 5185749. Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the
More informationSAFE HARBOUR 6/1/2015
SAFE HARBOUR This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationFORWARD LOOKING STATEMENTS
Jefferies 2014 Healthcare Conference November 19, 2014 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. Any statements contained herein which do not describe historical
More informationHealth Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona
Health Care Worldwide Crédit Suisse Global Credit Products Conference October 1, 2015 - Barcelona Safe Harbor Statement This presentation contains forward-looking statements that are subject to various
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationActive Biotech Group Annual Accounts Report January December Active Biotech invests in new pharmaceuticals against cancer
Active Biotech Group Annual Accounts Report January December 1999 Active Biotech invests in new pharmaceuticals against cancer Sale of Polio vaccine to new partner SAIK goes into clinical trials in MS
More informationPhylogica Harnessing biodiversity for biologics discovery
Phylogica Harnessing biodiversity for biologics discovery AGM November 2010 Introductions to Speakers Dr Douglas Wilson - Executive Chairman Former Senior Vice-President, Medicine for Boehringer Ingelheim
More informationForget Heart Disease: 1 Stock to Enjoy a Long, Healthy, Prosperous Retirement
Forget Heart Disease: 1 Stock to Enjoy a Long, Healthy, Prosperous Retirement Amgen: Delivering the Next Blockbuster Drug that Will Cure Heart Disease This California based biotech concern has been a public
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationMarch 13, Dear Shareholder:
15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive September 24, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 ContraFect Corp. (CFRX-NASDAQ)
More informationLife Sciences. Collaboration arrangement accounting. March 18, 2015
Life Sciences Collaboration arrangement accounting March 18, 2015 Disclaimer Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate
More informationSanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care
Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.
More informationJefferies Global Healthcare Conference Grand Hyatt, New York City 3 June 2015
UDG Healthcare plc An International Healthcare Services Organisation Jefferies Global Healthcare Conference Grand Hyatt, New York City 3 June 2015 1 FORWARD LOOKING STATEMENTS Some statements in this presentation
More informationSmall-Cap Research. GeoVax Labs Inc. (GOVX-OTC) GOVX: New Ebola vaccine program added, on track to advance its HIV vaccine programs- -Outperform
Small-Cap Research October 6, 2014 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 GeoVax Labs Inc. (GOVX-OTC) GOVX: New Ebola vaccine program added,
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationInvestor Presentation
Investor Presentation Spring 2011 NYSE Amex: PCYG www.parkcitygroup.com Forward Looking Statement Statements in this presentation that relate to Park City Group's future plans, objectives, expectations,
More informationANNUAL GENERAL MEETING. June 28, Network. Security. D a t a C e n t r e. Engineering. Integration L I F E C Y C L E S E R V I C E S
ANNUAL GENERAL MEETING June 28, 2017 Network Security Engineering D a t a C e n t r e L I F E C Y C L E S E R V I C E S Integration 1 Wade K. Dawe Chairman of the Board Kevin Shank President and Chief
More informationIntegrated Research Limited (IRI)
Integrated Research Limited (IRI) FY2016 Half Year Financial Results February, 2016 ABN: 76 003 588 449 9 of the top 10 US banks 4 of the world s 10 largest companies 5 of the 10 biggest stock exchanges
More informationBiotech lunch - Stockholm. 12 November 2009
Biotech lunch - Stockholm 12 November 2009 Rein Piir, CFO / IR Medivir contact rein.piir@medivir.se www.medivir.com Pipeline Project Indication(s) Partners/- date of Explorati Optimiz agreement Terms Medivir's
More informationBioCryst Reports Fourth Quarter and Full Year 2017 Financial Results. Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc.
BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc. Research Triangle Park, North Carolina February 27, 2018
More informationPharmaceutical Industry. Dr Gino Martini FRPharmS EIPG President
Challenges & Opportunities for the Pharmaceutical Industry Dr Gino Martini FRPharmS EIPG President Why do I enjoy being an Industrial Pharmacist? Something happened here Sir Alexander Fleming & his mouldy
More informationIntellectual Property and Academic- Industrial Collaboration
Intellectual Property and Academic- Industrial Collaboration J. Denry Sato, D.Phil Visiting Professor of Industry-Academia- Government Collaboration Hiroshima University Funding Problem for Educational
More informationIntroducing the DNA of innovation Case Competition at PA Consulting
Introducing the DNA of innovation Case Competition at PA Consulting Jarl Greve Morten Juhl Nadine Raida Sebastian Kersting BSc in International Business BSc in International Business BSc in International
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationEli Lilly and Company
Eli Lilly and Company Acquisition of ImClone Systems, Inc. October 6 th, 2008 SEC Disclosure During this conference call, we anticipate making projections and forward-looking statements that are based
More informationInvestor Update. September 2018 NASDAQ: PCOM TSX: PTS. Points International Ltd.
Investor Update September 2018 Points International Ltd. NASDAQ: PCOM TSX: PTS Safe Harbor This presentation contains or incorporates forward-looking statements within the meaning of the United States
More informationPresentation Q4 2016/17. October, 2017
Presentation Q4 2016/17 October, 2017 FINANCIAL REPORT Q4 2016/17 Dustin at a Glance 200,000 hardware and software products sold online Net sales Software and services ~11% Hardware Clients Server Offline
More informationPARKERVISION, INC. Rating: STRONG BUY Target: $27. NASDAQ: PRKR - $7.15 (Intra-Day Price) Semiconductors Integrated Circuits
EGE INSTITUTIONAL RESEARCH REPORT RESEARCH UPDATE MARCH 27, 2008 PARKERVISION, INC. NASDAQ: PRKR - $7.15 (Intra-Day Price) Semiconductors Integrated Circuits PRKR Ranks In The Top-Ten Of The Patent Board
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationBango 1h2018 results presentation
Bango 1h2018 results presentation 18 September 2018 Ray Anderson, CEO and co-founder Rachel Elias-Jones, CFO Anil Malhotra, CMO and co-founder Version 2018 Bango PLC bango.com Business highlights Payment
More informationSupplemental Financial Schedules May 19, 2015
Supplemental Financial Schedules May 19, 2015 The presentations and related schedules contain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP).
More informationGood morning and thank you for joining us for our quarterly update.
Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More informationStrategic Overview of the Biotechnology Industry
Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors General Presentation, Fresenius SE & Co. KGaA, Investor Relations Copyright, August 2016
More informationPositioned for Profitable Growth
Positioned for Profitable Growth 3Q 2017 NYSE: BLD FAST FACTS Largest Network in the U.S. 240+ Locations Exposure to 95% of all Housing Starts Nationwide Network Blended Capital Allocation Strategy Emphasizing
More informationMeet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer
Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer Written by Clara Rodríguez Fernández Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing
More informationResults for the year ended 31 March Richard Longdon, Chief Executive James Kidd, Chief Financial Officer
Results for the year ended 31 March 2012 Richard Longdon, Chief Executive James Kidd, Chief Financial Officer Safe Harbor Statement During (and in this) presentation we make forward-looking statements.
More informationRating Methodology by Sector. Pharmaceuticals
Last Updated: December 7, 2011 Rating Methodology by Sector Pharmaceuticals Pharmaceuticals are mainly categorized into ethical drugs, which are provided to patients by hospital pharmacies or by dispensing
More informationSecond Quarter Earnings Conference Call. Friday, August 4, 2017 Wesley College, Dover, DE
Second Quarter Earnings Conference Call Friday, August 4, 2017 Wesley College, Dover, DE Forward Looking Statements and Other Disclosures Safe Harbor Statement: Some of the Statements in this document
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationPromotion and Development Collaborations Between Established Players
Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com
More informationFresenius Investor News
health care worldwide August 3, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationWinter/spring 2017/18. CEO Lars Marcher
Winter/spring 2017/18 CEO Lars Marcher Agenda About Ambu Q1 highlights Potential in Visualisation Financials and outlook Q&A Disclaimer Forward-looking statements, especially such relating to future sales
More informationUDG Healthcare plc Annual General Meeting 2018
UDG Healthcare plc Annual General Meeting 2018 Tuesday 30th January 2018, Dublin Brendan McAtamney, CEO At a Glance UDG Healthcare is a leading international partner of choice delivering advisory, communication,
More informationCase Study:! From humble beginnings to world s largest biotech. September 29, 2104
Case Study:! From humble beginnings to world s largest biotech September 29, 2104 Today:! Amgen is world s largest biotechnology company Deal exclusively with biologics 20,000 global employees in North
More informationSmall-Cap Research. ContraFect Corp. (CFRX-NASDAQ) CFRX: CF-301 Phase 1 Results Presented at ECCMID Conference UPDATE SUMMARY DATA ZACKS ESTIMATES
Small-Cap Research April 12, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 ContraFect Corp. (CFRX-NASDAQ) CFRX: CF-301 Phase 1 Results Presented
More information